East Coast, USA-based Finch Therapeutics (Nasdaq: FNCH), a specialist in oral biologics, has deepened its partnership with Japan's Takeda Pharmaceutical (TYO: 4502).
Building on an agreement reached in 2017, Takeda will now take over leadership of the program for FIN-524, now known as TAK-524, in ulcerative colitis.
The investigational, orally administered therapy is a targeted consortia product composed of both spore-forming and non-spore-forming specially selected bacterial strains.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze